Therapeutic Response

CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in combination with Cyclophosphamide, Doxorubicin, and Prednisone in patients with Peripheral T-Cell lymphoma, NOS.

Statements

Source and description